Knowledge Library

iMN041: Prodrug with a Unique Antitumor Immune Response

WuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses generated by iMN041, a prodrug of a DNA methyl transferase/ribonucleotide reductase inhibitor.  This study also assessed the efficacy of iMN041 in mouse xenografts of human clear cell renal cell cancer, pancreatic cancer, and triple negative …Read More >

Resource Type: Latest Science Publication
Resource Topic: Cell-based Assays Immunology Oncology Tumor Models

VIEW

One Stop Target-to-Hit Platform: STATs

STAT proteins are key mediators of cellular immunity, proliferation, apoptosis, and differentiation.  STATs are known to play a role in the pathogenesis of many different diseases (including cancer) and the development of drugs directly or indirectly targeting STAT signaling has become a major focus for discovery teams.  WuXi AppTec offers a comprehensive platform of biophysical …Read More >

Resource Type: Brochure
Resource Topic: Biochemical Assays Biophysical Assays Immunology Oncology Structural Biology

VIEW

Dianthus Platform: Screening for Modulators of SIK3

Salt-inducible kinases (SIKs) have recently emerged as key regulators of oncogenesis, inflammation, and immune responses, making these enzymes an important drug target. The isoform SIK3 is a novel regulator of tumor-intrinsic resistance to cytotoxic T cell attack. To support the discovery of novel SIK3 modulators, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays …Read More >

Resource Type: Brochure
Resource Topic: Autoimmune and Inflammatory Diseases Biophysical Assays Hit Finding Hit-to-Lead Immunology Metabolic Diseases Oncology

VIEW

Dianthus Platform: Screening for CRBN-DDB1 Proteolysis-Targeting Chimeras and Molecular Glues

Cereblon (CRBN) forms an E3 ligase complex together with DDB1, CUL4, and RBX1. CRBN functions as a substrate receptor of this complex for the recognition and binding of proteins targeted for ubiquitination and proteasomal degradation.  To support the discovery of CRBN-DDB1 proteolysis-targeting chimeras and molecular glues, WuXi AppTec offers an integrated platform of ready-to-go assays …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Cardiovascular & Metabolic Diseases Central Nervous System & Pain Hit Finding Hit-to-Lead Immunology Infectious Diseases Oncology

VIEW

Dianthus Platform: Screening for Modulators of STING

The adaptor protein STING (stimulator of interferon genes) has emerged as an exciting target for both immunological conditions (STING inhibition) and cancer therapies (STING activation).  To support drug discovery teams in the discovery of novel modulators of STING, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays and Dianthus, a plate-based and microfluidics-free affinity …Read More >

Resource Type: Brochure
Resource Topic: Biophysical Assays Hit Finding Hit-to-Lead Immunology Oncology

VIEW

Jurkat Reporter Cell Lines for Immunotherapy Drug Screening

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Cells and Protein Science Immunology Oncology

VIEW

In Vitro Immunology Assay Platform

Leverage our panel of in vitro immunology assays to accelerate your lead optimization efforts.  WuXi AppTec offers a comprehensive platform of immune profiling services, including ligand/receptor binding for target validation and cell-based functional assays to characterize both innate and adaptive immune responses. Our end-to-end services panel includes suppressive assays, mixed lymphocyte reactions, mast cell degranulation assays, …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Immunology Lead Optimization

VIEW

CD34+ Hematopoietic Stem Cell Differentiation Platform

To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell differentiation platform.  Our panel includes neutrophil, eosinophil, erythroid, and mast cell differentiation, as well as monocyte/macrophage differentiation and polarization, and megakaryocyte/platelet differentiation. Check out our comprehensive platform of immune profiling and biomarker services

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Hit-to-Lead Immunology

VIEW

Drug Resistant Models

Comprehensive portfolio of drug resistant models representing clinically relevant mechanisms of resistance: 10+ cancer types 25+ key targets 30+ leading drugs 100+ resistant models Extensive validation data Our capabilities include cutting-edge bioinformatics and analytical techniques to enable a clear and in-depth understanding of resistance mechanisms View our AACR poster describing the establishment of a wide …Read More >

Resource Type: Brochure
Resource Topic: Immunology in vivo Pharmacology

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!